In a patient with long untreated slow-growing osteoblastic bone metastases from an ER/PgR negative breast carcinoma, new metastatic sites in many lymphnodes pleura and massively in liver have been observed 4 weeks after receiving tamoxifen. Cause-effect relationship between administration of the drug and this unusually rapid spreading of the disease may be considered only as a hypothesis, as it is based wholly on clinical outcome. However, reporting of any exacerbation of breast cancer apparently induced by tamoxifen, even if only anecdotal, is advisable.
Get full access to this article
View all access options for this article.
References
1.
AgrawalB.L., ZelkowitzL.: Bone « flare », hypercalcemia and jaundice after tamoxifen therapy.Arch. Int. Med.,141: 1240, 1981.
2.
BaumM.: The role of endocrine therapy in primary breast cancer. Abstracts 3rd Internat. Conference on Adjuvant Therapy of Primary Breast Cancer. St Gallen, session 6/15, March 2-5, 1988.
3.
BozzettiC., NaldiN., GuazziA.M., NizzoliR., BenecchiM., CocconiG.: Determination of estrogen receptors in human breast cancer. Comparison between enzyme immunoassay and dextran-coated charcoal method.Tumori,72: 511–514, 1986.
BruchovskyN., GoldieJ.H.: Basis for the use of drug and hormone combinations in the treatment of endocrine related cancer. In: Drug and Hormone Resistance in Neoplasm.Boca Raton.Fla. CRC, p. 2178, 1983.
6.
CarterS.K.: Predictors of response and their clinical evaluation.Cancer Chemother. Pharmacol.,7: 1–4, 1981.
7.
CechP., BlockJ.B., ConeL.A., StoneR.: Tumor lysis syndrome after tamoxifen flare.New Engl. J. Med.,315: 263–264, 1986.
8.
CocconiG., Di BlasioB., BisagniG., AlbertiG., BottiE., AnghinoniE.: Neoadjuvant chemotherapy or chemotherapy and endocrine therapy in locally-advanced breast carcinoma. A prospective randomized study.Am. J. Clin. Oncol. (in press).
9.
ConteP.F., FraschiniG., AlamaA., NicolinA., CorsaroE., CanaveseG., RossoR., DrewinkoB.: Chemotherapy following estrogen induced expansion of the growth fraction of human breast cancer.Cancer Res.,45: 5926–5930, 1985.
10.
FerrazziE., CarteiG., De BesiP., FornasieroA., PalùG., PaccagnellaA., SperandioP., FosserV., GrigolettoE., FiorentinoM.: Tamoxifen in disseminated breast cancer.Tumori,63: 463–468, 1977.
11.
FerrazziE., CarteiG., MattarazzoR., FiorentinoM.: Oestrogenic-like effect of tamoxifen on vaginal epithelium.Brit. Med. J.,1: 1351–1352, 1977.
12.
FisherB., RedmondC., BrownA., WolmarkN., WittlifJ., FisherE.R., PlotkinD., BowmanD., SachsS., WolterJ., FrelickR., DesserR., LicalziN., GeggieP., CampbellT., EliasG., PragerD., KoontzP., VolkH., ShibataH.: Treatment of primary breast cancer with chemotherapy and tamoxifen.New Engl. J. Med.,305: 1–6, 1981.
13.
FisherB., RedmondC., BrownA., WickerhamD.L., WolmarkN., AllegraJ., EscherG., LippmanM., SavlovE., WittliffJ., FisherE.R.: Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.J. Clin. Oncol.,1: 227–241, 1983.
14.
FowlerJ.E.Jr., WhitmoreW.F.: The response of metastatic adenocarcinoma of the prostate to exogenous testosterone.J. Urol.,126: 372–375, 1981.
15.
GoldhirschA., GelberR.: Adjuvant treatment for early breast cancer: the Ludwig Breast Cancer Studies. Proceed of the NIH Consensus Development Conference on Adjuvant Chemotherapy and Endocrine Therapy for Breast Cancer.NCI monographs,1: 55–70, 1986.
16.
HarperM.J.K., WalpoleA.L.: A new derivative of triphenil-ethilene: effect on implantation and mode of action in rats.J. Reprod. Fertil.,13: 101–119, 1967.
17.
HartleyJ.W., WongJ., FletcherW.S.: Response of advanced breast cancer to total endocrine ablation after exacerbation on tamoxifen: results in seven patients and possible mechanisms of action.J. Surg. Oncol.,34: 182–187, 1987.
18.
HeelR.C., BrogdenR.N., SpeightT.M., AveryG.S.: Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer.Drugs,16: 1–24, 1978.
19.
KatzenellenbogenB.S., MillerM.A., MullickA., SheenY.Y.: Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites. Breast Cancer Res.Treat.,5: 231–243, 1985.
20.
KiangD.T., KennedyB.J.: Tamoxifen (antiestrogen) therapy in advanced breast cancer.Am. Int. Med.,87: 687–690, 1977.
LernerH.J., BandP.R., IsraelL., LeungB.S.: Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer.Cancer Treat. Rep.,60: 1431–1435, 1976.
23.
LippmanM.E., DicksonR.B., BatesS., KnabbeC., HuffK., SwainS., McManawayM., BronzertD., KasidA., GelmannE.P.: Autocrine and paracrine growth regulation of human breast cancer.Breast Cancer Research and Treatment,7: 59–70, 1986.
24.
McintoshI.H., ThyneG.S.: Tumor stimulation by antioestro-gens.Br. J. Surgery,64: 900–901, 1977.
25.
MehtaR.G., CernyW.L., MoonR.C.: Distribution of antiestrogen-specific binding sites in normal and neoplastic mammary gland.Oncology,41: 387–392, 1984.
26.
MintonM.J., CantwellB.M.J., KnightR.K., RubensR.D., HaywardJ.L.: Safety of tamoxifen.Lancet,1: 396–397, 1978.
27.
MorganL.R.Jr., ScheinP.S., WolleyP.V.: Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters.Cancer Treat. Rep.,60: 1437–1443, 1976.
28.
MouridsenH.T., AndersenA.P., BrinckerH., DombernowskyP., RoseC., AndersenK.W.: Adjuvant tamoxifen in postmenopausal high-risk breast cancer patients: present status of Danish Breast Cancer Cooperative Group Trials. Proceed of the NIH Consensus Development Conference on Adjuvant Chemotherapy and Endocrine Therapy for Breast Cancer.NCI monographs,1: 115–118, 1986.
29.
MouridsenH., PalshofT., PattersonJ., BattersbyL.: Tamoxifen in advanced breast cancer.Cancer Treat. Rev.,5: 131–141, 1978.
30.
NenciI.: Estrogen receptor cytochemistry in human breast cancer: status and prospects.Cancer,48: 2674–2686, 1981.
31.
NIH Consensus Development Conference on Adjuvant Chemotherapy and Endocrine Therapy for Breast Cancer.Introduction and Conclusions.Proceed of the NIH Consensus Development Conference on Adjuvant Chemotherapy and Endocrine Therapy for Breast Cancer. NCI monographs, 1: 1–4, 1986.
32.
OsborneC.K., HobbsK., ClarkG.M.: Effects of estrogen and antiestrogens on growth of human breast cancer cells in athymic nude mice.Cancer Res.,45: 584–590, 1985.
33.
PattersonJ.S., BattersbyL.A., EdwardsD.G.: Review of the clinical pharmacology and international experience with tamoxifen in advanced breast cancer.Rev. Endocrine Related Cancer, suppl.9: 563–582, 1982.
34.
PattersonJ.S., BaumM.: Safety of tamoxifen.Lancet,1: 105, 1978.
35.
PlotkinD., LechnerJ.L., JungW.E., RosenP.G.: Tamoxifen flare in advanced breast cancer.JAMA,240: 2644–2646, 1978.
36.
PritchardK.I., MeakinJ.W., BoydN.F., AmbusU., DeBoerG., DemboA.J., EvansW.K., SutherlandD.J.A., WilkinsonR.H., BassettA.: Adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer: an uptade.Proceed ASCO,6: 61, 1987.
37.
ReddelR.R., SutherlandR.L.: Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare.Eur. J. Cancer Clin. Oncol.,20: 1419–1424, 1984.
38.
SainsburyJ.R., FarndonJ.R., SherbetG.V., MarrisA.L.: Epidermal growth-factor receptors and oestrogen receptors in human breast cancer.Lancet,1: 364–366, 1985.
39.
SilvestriniR., DaidoneM.G., GaspariniG.: Cell kinetics as prognostic marker in node-negative breast cancer.Cancer,56: 1982–1987, 1985.
40.
StollB.A.: The significance of tumor «stimulation» by tamoxifen.In: Endocrine Treatment of Breast Cancer,HenningsonB., LinderF., SteicheleC., vol. 17, pp. 149–150, Springer-Verlag, New York, 1980.
41.
TormeyD.C., GrayR., TaylorS.G., KnuimanM., OlsonJ.E., CummingsF.J.: Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer. Proceed of the NIH Consensus Development Conference on Adjuvant Chemotherapy and Endocrine Therapy for Breast Cancer.NCI monographs,1: 75–80, 1986.
42.
TormeyD.C., SimonR.M., LippmanM.E., BullJ.M., MeyersC.E.: Evaluation of tamoxifen dose in advanced breast cancer.Cancer Treat. Rep.,60: 1451–1455, 1976.
43.
VillalonA.H., TattersallM.H.N., FoxR.M., WoodsR.L.: Hypercalcemia after tamoxifen for breast cancer: a sign of tumor response? Br.Med. J.,2: 1329–1330, 1979.
44.
WeintraubJ., WeintraubD., RedardM., VassilakosP.: Evaluation of estrogen receptors by immunocytochemistry on fine-needle aspiration biopsy specimens from breast tumors.Cancer,60: 1163–1172, 1987.
